Developer of pharmaceutical innovations for the treatment of diabetes. The company's goal is to commercialize new concepts of treatment and enable continual delivery of novel drugs both for diabetes itself and for the complications that the disease induces.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Grant | 26-Sep-2013 | $3.33M | Completed | Startup | ||
2. Merger/Acquisition | 29-Apr-2002 | Completed | Startup | |||
1. Early Stage VC | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Per-Olof Berggren Ph.D | Founder, Chief Executive Officer & Board Member | ||
Catharina Rahm | Chief Financial Officer |
Name | Representing | Role | Since |
---|---|---|---|
Claes-Henrik Julander | Self | Board Member | 000 0000 |
Gunnar Olsson Ph.D | Self | Board Member | 000 0000 |
Kenth Petersson | Self | Chairman | 000 0000 |
Martin Nicklasson Ph.D | Self | Board Member | 000 0000 |
Per-Olof Berggren Ph.D | BioCrine | Founder, Chief Executive Officer & Board Member | 000 0000 |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
HealthCap | Venture Capital | Minority | 000 0000 | 000000 0 |